The Patent Finder
PF

Pierre Fabre Medicament

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

57 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Aug 2027
Next term end
41
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for IGF-1R Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer (US 11,661,457) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 2 fees due Dec 11 to 13, 2026 · next Dec 11
  • 3 fees due Mar 1 to 24, 2027 · next Mar 1
  • 2 fees due Apr 22 to 29, 2027 · next Apr 22
  • 1 fee due May 3, 2027
    The maintenance fee for Novel Antigen Binding Protein and Its Use as Addressing Product for the Treatment of Cancer (US 9,173,962) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 2 fees due Jun 30, 2027
  • 2 fees due Jul 16 to 28, 2027 · next Jul 16
  • 1 fee due Aug 4, 2027
    The maintenance fee for Method for Treating Movement Disorders with Befiradol (US 10,548,885) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 1 fee due Sep 5, 2027
    The maintenance fee for Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer (US 11,918,656) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for IGF-1R Antibody-Drug-Conjugate and Its Use for the Treatment of Cancer (US 10,633,448) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 41 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 8,309,128Stabilized Milnacipran Formulation
In force
 · High confidence
In forceHigh confidence
US 8,329,173Antibodies Inhibiting C-Met Dimerization and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,011,865Combination of a C-Met Antagonist and an Aminoheteroaryl Compound for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 8,834,923Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,623,359Combination of a C-Met Antagonist and an Aminoheteroaryl Compound for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 8,673,302Anti-Cmet Antibody and Its Use for the Detection and the Diagnosis of Cancer
In force
 · High confidence
In forceHigh confidence
US 8,734,784Composition Comprising a Combination of an Elder Extract and a Strain of L. Paracasei, L. Bulgaricus or S. Thermophilus
In force
 · High confidence
In forceHigh confidence
US 8,604,241Method for Synthesis of (1S, 2R)-MILNACIPRAN
In force
 · High confidence
In forceHigh confidence
US 8,946,225Derivatives of 2H Pyridazin- 3 -Ones, Their Preparation and Their Use as SCD-1 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,741,290ANTI-cMET ANTIBODY
In force
 · High confidence
In forceHigh confidence
10 of 57 patents shown.
Pro members see all 57.
Pro members: see all 57 patents
Also on record, not counted in the 57: 5 patents in force now held by others · 113 patents ended · 15 applications pending · 111 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited